What's On

VIC Stem Cell Network - Monthly Seminar Series (April 2013)

04:00 AM - Tuesday 09 April, 2013

On Tuesday 9th April at 4pm, Professor David Haylock,  Stream Leader, Stem Cell Research, Materials Science and Engineering, CSIRO will be our guest speaker.

Please note change of venue – Ground Floor, Education Centre, Melbourne Brain Centre, The University of Melbourne and as the first Tuesday of this month is Easter Tuesday we will be conducting this seminar on the 2nd Tuesday of the month – the 9th April.

David is best known for his pioneering work on blood stem cell mobilization and transplantation and long term interests in ex vivo manipulation of haemopoietic stem cells (HSC). From 2000-2005, as Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre in Melbourne, Australia, David led Australia’s first clinical trial with ex vivo expanded CD34+ cells in the setting of repetitive high dose chemotherapy for metastatic breast cancer. David is currently an ARC Future Fellow and Science Leader within the Material Science and Engineering division of CSIRO. His group investigates stem cell-material interactions and a key focus is development of bioreactor technology for growth of megakaryocytes and platelets for transfusion.


“Bio-manufacturing challenges in producing human platelets for transfusion"


Generation of functional platelets for transfusion is a difficult biological and technical challenge given that at least 1 x 1012 platelets would need to be generated from a limited number of haemopoietic stem cells. Our approach involves optimization of three linked stages including HSC expansion, megakaryocyte differentiation and maturation and finally conversion of large polyploid megakaryocytes into functional platelets. The approaches being adopted are inspired by a desire to replicate key features of the haemopoietic stem cell niche and the intimate contact between megakaryocytes and endothelial cells within bone marrow sinusoids. The presentation will highlight recent progress in the design and testing of prototype, two chamber perfusion-based bioreactors for this purpose.